Oncology Frontier  : Professor Huang， you just made a speech on the strategy of optimized haploidentical transplantation， and the successful transplantation across the HLA barrier.  The treatment is recognized worldwide.  Can you please talk about the transplantation model?

 

　　《肿瘤瞭望》：您在这次会议关于单倍型造血干细胞移植的选择策略非常吸引听众，该移植成功地跨越了HLA屏障，这种独特模式得到了国内外学者的一致认同。请您谈谈该移植模式。

 

　　Professor Huang  : Actually I think transplantation is one of the most effective and sometimes most curative therapy for many kinds of hematological malignancies.  Actually it is a really big problem， at least in the last 15 to 20 years.  As explained by Dr. Bacigalupo we now have several forms that have identical transplantation so the time where everyone can have a donor is arriving.

 

　　黄教授：实际上我认为移植是最有效的，用于多种恶性血液病的最有效的治疗。至少在过去的15到20年，实际上它是一个真正的大问题。正如Bacigalupo博士所解释，我们现在许多种形式个体化的移植模式，所以移植的时机是让每个病人都能寻找到供体。

 

　　Oncology Frontier  : President Chomienne， what is your comment on transplantation strategies?

 

　　《肿瘤瞭望》：请问C.Chominne主席，您对此种移植策略选择的看法？

 

　　President Chomienne : I completely agree.  Transplantation is for the moment one of the rare cures of hematological diseases and that the registries for the donors are crucial and therefore the attempt and the resources of the clinical trials are very important.

 

　　Chomienne教授：我完全同意。移植是目前治疗罕见的血液病的一种治疗，捐赠者登记是至关重要的，因此，临床试验的资源的尝试也是非常重要的。

 

　　Oncology Frontier  : Thank you.  Last question， what is your dream for the future of the EHA?

 

　　《肿瘤瞭望》：谢谢，最后一个问题，请问您队EHA未来的梦想？

 

　　President Chomienne : My dream for the future of EHA is to continue to have as many countries participating in our congress and also that outside of the congress we continue to all work together and that the clinical trials and the research programs are not limited to just one country or one continent.

 

　　Chomienne教授：我对EHA未来的梦想是继续有更多的国家参加我们的大会，同时在会议外我们继续一起工作，研究计划不仅仅是一个国家或一个欧洲大陆的临床试验。

 

　　（来源：肿瘤瞭望编辑部）